Bayer Animal Health Aims To Grow Animal Health Business, R&D Budget

Bayer AG (BAYN.XE) of Germany wants to grow its animal health-care activities through acquisitions and by increasingly tapping new innovations used in treating human diseases to formulate therapies for cats and canines, said Andreas Busch, head of global drug discovery at the company. "It would be stupid not to be looking in the present environment for assets in animal health, and we continue to look at attractive assets as they become available, because we believe the animal health business could be a very important pillar of our overall diversified health care strategy," Busch told Dow Jones Newswires.